
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
The authors describe the use of convergence chromatography combined with mass spectrometry for impurity profiling.
The authors describe the use of convergence chromatography combined with mass spectrometry for impurity profiling. This was achieved by using metoclopramide and its related substances and metoclopramide drug products as examples.
View
.
over 13 years ago
Identification and Quantification of Trace-Level Protein Impuritiesover 13 years ago
Ultra-High-Speed Analysis of Ibuprofen Using HPLC




